Research Paper Advance Articles

Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma

TNS3 promotes ESCC cell proliferation. (A) EdU incorporation and (B). CCK-8 assay of KYSE150 transfected with siTNS3 (#1, #2) and siNC for 48 hr. Scale bar = 50 μm. (C) Subcutaneous tumor volumes and (D). weights of the xenograft mice model (expressed shTNS3#1, #2, shNC). Scale bar = 0.5 cm. (E) Immunostaining of TNS3 and Ki-67 in the subcutaneous tumor blocks (shTNS3 #2 and shNC). Scale bar = 100 μm. (F) Growth curves of TE-1 and TE-7 treated with LMK-235 for 48 hr post-transfection with siTNS3(#2). Absorbance at OD450 nm are normalized to vehicle control (0.1% DMSO; n = 5 wells/dose point). IC50 of cells transfected with siTNS3(#2) are marked as grey (TE-1) and red (TE-7) point, respectively. (A–D, F) Error bar denotes SEM of three replicates.

Figure 5. TNS3 promotes ESCC cell proliferation. (A) EdU incorporation and (B). CCK-8 assay of KYSE150 transfected with siTNS3 (#1, #2) and siNC for 48 hr. Scale bar = 50 μm. (C) Subcutaneous tumor volumes and (D). weights of the xenograft mice model (expressed shTNS3#1, #2, shNC). Scale bar = 0.5 cm. (E) Immunostaining of TNS3 and Ki-67 in the subcutaneous tumor blocks (shTNS3 #2 and shNC). Scale bar = 100 μm. (F) Growth curves of TE-1 and TE-7 treated with LMK-235 for 48 hr post-transfection with siTNS3(#2). Absorbance at OD450 nm are normalized to vehicle control (0.1% DMSO; n = 5 wells/dose point). IC50 of cells transfected with siTNS3(#2) are marked as grey (TE-1) and red (TE-7) point, respectively. (AD, F) Error bar denotes SEM of three replicates.